INFLUENZA DIAGNOSTICS MARKET ANALYSIS

Name: Influenza Diagnostics Market News
Creator: Coherent Market Insights
License: https://www.coherentmarketinsights.com/privacy-policy

Influenza Diagnostics Market, by Test Type (Traditional Diagnostic Test and Molecular Diagnostic Assays), by End User (Hospitals and Clinics, Reference Laboratories, and Others), and by Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022-2028

Key Development

In February 2019, Abbott Laboratories launched reformulated BinaxNow A & B Card 2 rapid Influenza test. BinaxNow A & B Card 2, which is an in vitro immunochromatographic assay for the detection of influenza.
In February 2019, Eurofins Viracor, Inc., has introduced aloxavir marboxil (XOFLUZA) Influenza which is an Antiviral Resistance PCR test for the detection of I38T/M/F mutations in H3N2.
In 2018, Sekisui Diagnostics launched Silaris Influenza A&B test in collaboration with Mesa Biotech, Inc.
In 2018, Abbott Laboratories, acquired Alere Inc., a diagnostic device and service provide, which strengthened the company's diagnostics presence in the global market.